Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

GNFT

Genfit ADR

Nov 19 • 04:00PM ET

4.85

0.00 0.00 %

Healthcare • Biotechnology • France • NASD

Peers: GILD ARWR VKTX MDGL ETNB NBIX ALKS PTGX RDHL PRQR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.90	Insider Own	-	Shs Outstand	50.00M	Perf Week	11.75%
Market Cap	242.51M	Forward P/E	-	EPS next Y	-0.22	Insider Trans	-	Shs Float	43.78M	Perf Month	14.12%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	0.14%	Short Float	0.05%	Perf Quarter	17.72%
Income	-	P/S	-	EPS this Y	-716.67%	Inst Trans	-	Short Ratio	2.19	Perf Half Y	12.27%
Sales	-	P/B	-	EPS next Y	-18.92%	ROA	-	Short Interest	0.02M	Perf YTD	30.55%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	4.93 -1.61%	Perf Year	-6.94%
Cash/sh	-	P/FCF	-	EPS past 3/5Y	-73.57% -	ROIC	-	52W Low	2.55 90.20%	Perf 3Y	25.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.51% -	Gross Margin	-	Volatility	8.52% 5.67%	Perf 5Y	24.04%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-274.42%	Oper. Margin	-	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-44.94%	Profit Margin	-	RSI (14)	67.79	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-	SMA20	15.35%	Beta	0.70	Target Price	7.33
Payout	-	Debt/Eq	-	Sales Q/Q	-41.80%	SMA50	17.68%	Rel Volume	0.00	Prev Close	4.85
Employees	188	LT Debt/Eq	-	Earnings	Sep 22 AMC	SMA200	23.00%	Avg Volume	9.28K	Price	4.85
IPO	Mar 27, 2019	Option/Short	No / No	EPS/Sales Surpr.	-119.78% -64.28%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-25	Resumed	H.C. Wainwright	Buy	$9
Dec-20-21	Upgrade	H.C. Wainwright	Neutral → Buy	$8
Jul-23-20	Upgrade	Stifel	Hold → Buy
Jun-25-20	Initiated	BofA/Merrill	Underperform	$7
May-13-20	Downgrade	Kepler	Buy → Reduce
May-12-20	Downgrade	H.C. Wainwright	Buy → Neutral	$46 → $11
May-12-20	Downgrade	Barclays	Overweight → Equal Weight	$55 → $14
Oct-29-19	Reiterated	B. Riley FBR	Buy	$52 → $43
Jun-25-19	Initiated	Stifel	Hold
Apr-24-19	Initiated	SVB Leerink	Outperform	$58
Apr-22-19	Initiated	Barclays	Overweight

Show Previous Ratings

Jul-28-25 02:27AM	Kepler Capital Maintained a Buy Rating on Genfit (GNFT) (Insider Monkey)
Jul-08-25 04:10PM	Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
Jun-17-25 02:30PM	GENFIT: June 17, 2025 Combined Shareholders Meeting Results (GlobeNewswire)
May-22-25 04:10PM	GENFIT Reports First Quarter 2025 Financial Information (GlobeNewswire)
May-20-25 04:10PM	GENFIT to receive a 26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo in Italy (GlobeNewswire)
04:10PM	Loading…
May-14-25 04:10PM	GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) (GlobeNewswire)
May-07-25 04:10PM	GENFIT Annual Combined General Meeting of June 17, 2025 - Availability of Preparatory Documents (GlobeNewswire) -8.01%
May-05-25 01:30AM	GENFIT to Present Latest ACLF Research at EASL Congress 2025 (GlobeNewswire) +5.89%
Apr-29-25 03:10PM	GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F (GlobeNewswire) +10.37%
Apr-28-25 04:10PM	GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025 (GlobeNewswire)
Apr-24-25 04:10PM	GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-20-25 05:10PM	GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders (GlobeNewswire)
Mar-10-25 05:10PM	Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs (GlobeNewswire)
Feb-27-25 04:10PM	GENFIT Announces Revenues and Cash Position as of December 31, 2024 (GlobeNewswire)
Feb-21-25 02:30AM	GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders general meeting (GlobeNewswire)
01:30AM	Loading…
Feb-10-25 01:30AM	GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders (GlobeNewswire)
Feb-06-25 04:10PM	GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025 (GlobeNewswire)
Jan-30-25 02:40AM	GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan (GlobeNewswire) +6.43%
Jan-29-25 04:10PM	GENFIT Announces 2025 Financial Calendar (GlobeNewswire)
Jan-13-25 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
Nov-13-24 04:10PM	GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 (GlobeNewswire) -12.96%
Nov-07-24 04:10PM	GENFIT Reports Third Quarter 2024 Financial Information (GlobeNewswire) -8.41%
Sep-23-24 01:30AM	GENFIT: Ipsens Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval (GlobeNewswire)
Sep-19-24 04:10PM	GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +15.51%
Jul-26-24 07:45AM	GENFIT: Positive Opinion from EMA Committee for Ipsens Iqirvo® (elafibranor) in Primary Biliary Cholangitis (GlobeNewswire) -11.28%
Jul-09-24 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
Jun-17-24 04:10PM	GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH (GlobeNewswire)
Jun-10-24 05:22PM	GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsens Iqirvo® for Primary Biliary Cholangitis (GlobeNewswire) -6.59%
May-29-24 04:10PM	GENFIT to Present Latest ACLF Research at EASL Congress 2024 (GlobeNewswire) +11.85% +14.07%
May-22-24 12:05PM	GENFIT: May 22, 2024 Combined Shareholders Meeting Results (GlobeNewswire) +8.29%
04:10PM	Loading…
May-14-24 04:10PM	GENFIT Reports First Quarter 2024 Financial Information (GlobeNewswire)
Apr-25-24 04:10PM	GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023) (GlobeNewswire)
Apr-15-24 04:10PM	GENFIT Annual Combined General Meeting of May 22, 2024 Availability of Preparatory Documents (GlobeNewswire)
Apr-05-24 02:00PM	GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F (GlobeNewswire)
Apr-04-24 04:10PM	GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-29-24 04:10PM	GENFIT Announces Revenues and Cash Position as of December 31, 2023 (GlobeNewswire) -7.31%
Jan-15-24 04:10PM	GENFIT Announces 2024 Financial Calendar (GlobeNewswire)
Jan-11-24 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
Dec-08-23 01:55AM	GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC) (GlobeNewswire) +7.34%
Dec-07-23 05:15AM	Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC (GlobeNewswire)
Dec-06-23 11:30AM	GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials (GlobeNewswire)
Nov-16-23 04:10PM	GENFIT Highlights ACLF Development Strategy at ACLF Day during AASLD The Liver Meeting® 2023 (GlobeNewswire)
Nov-13-23 04:30PM	GENFIT: Results from Ipsens ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine (GlobeNewswire)
Nov-09-23 04:10PM	GENFIT Reports Third Quarter 2023 Financial Information (GlobeNewswire)
Nov-02-23 05:10PM	GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023 (GlobeNewswire) +5.02%
Sep-26-23 04:10PM	GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology (GlobeNewswire)
Sep-20-23 04:10PM	GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -9.41%
Sep-05-23 04:10PM	GENFIT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 04:10PM	GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+ in Older Patients in Hepatology Communications (GlobeNewswire)
Jul-12-23 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
Jun-30-23 01:00AM	Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease (GlobeNewswire) -12.59%
Jun-07-23 04:10PM	GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023 (GlobeNewswire)
May-31-23 04:44PM	Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF) (PR Newswire)
04:10PM	GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset (GlobeNewswire)
May-24-23 01:00PM	GENFIT: May 24, 2023 Combined Shareholders Meeting results (GlobeNewswire)
May-23-23 04:10PM	GENFIT Announces Publication of the Development and Validation of NIS2+ in the Journal of Hepatology (GlobeNewswire)
May-11-23 04:10PM	GENFIT Reports First Quarter 2023 Financial Information (GlobeNewswire)
May-09-23 04:10PM	GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program (GlobeNewswire)
Apr-27-23 04:10PM	GENFIT Announces Publication of Extra-Financial Performance Report 2022 (GlobeNewswire)
Apr-19-23 04:10PM	GENFIT Annual Combined General Meeting of May 24, 2023 Availability of Preparatory Documents (GlobeNewswire)
Apr-18-23 04:10PM	GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F (GlobeNewswire)
Apr-13-23 04:10PM	GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-28-23 04:10PM	GENFIT Announces Revenues and Cash Position as of December 31, 2022 (GlobeNewswire)
Jan-30-23 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
Jan-24-23 04:10PM	GENFIT Announces 2023 Financial Calendar (GlobeNewswire)
Jan-05-23 04:10PM	GENFIT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-17-22 04:10PM	GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases (GlobeNewswire)
Nov-10-22 04:10PM	GENFIT Reports Third Quarter 2022 Financial Information (GlobeNewswire)
Oct-25-22 04:10PM	GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+ in NASH to be Presented at the AASLD Liver Meeting® (GlobeNewswire) +8.01%
Sep-29-22 04:10PM	GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis (GlobeNewswire) -6.65%
Sep-28-22 04:10PM	GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-19-22 12:42PM	Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases (Benzinga)
01:30AM	GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases (GlobeNewswire)
Sep-13-22 04:10PM	FDA Grants GENFITs GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma (GlobeNewswire)
Jul-08-22 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire) +9.62%
11:12AM	The NASH Drug Dream Isnt Dead Yet. Intercept is Asking FDA for Approval Again. (Barrons.com)
May-25-22 04:10PM	GENFIT: May 25, 2022 Combined Shareholders Meeting results (GlobeNewswire)
May-11-22 04:10PM	GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS) (GlobeNewswire) +7.58% -7.32%
Apr-29-22 04:10PM	GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022 (GlobeNewswire)
Apr-20-22 04:10PM	GENFIT Annual Combined General Meeting of May 25, 2022 Availability of Preparatory Documents (GlobeNewswire)
Apr-14-22 12:00PM	What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock (Zacks)
Apr-07-22 04:10PM	GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-28-22 04:10PM	GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021 (GlobeNewswire)
Jan-24-22 04:10PM	GENFIT: 2022 Financial Calendar (GlobeNewswire) -7.83%
Jan-21-22 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
Jan-11-22 10:00AM	Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-23-21 10:00AM	How Much Upside is Left in GENFIT S.A. Unsponsored ADR (GNFT)? Wall Street Analysts Think 60% (Zacks)
Dec-17-21 11:42AM	GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters (InvestorPlace) +53.31%
06:25AM	Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful (Benzinga)
01:15AM	On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset (GlobeNewswire)
01:00AM	Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership (Business Wire)
01:00AM	GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership (GlobeNewswire)
Nov-18-21 04:15PM	GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technologys Unique Performance in Identifying Patients with at-risk NASH (GlobeNewswire)
Nov-09-21 04:10PM	GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program (GlobeNewswire)
Nov-08-21 04:10PM	GENFIT: Third Quarter 2021 Financial Information (GlobeNewswire)
Nov-02-21 05:10PM	New Clinical Data on GENFITs Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting® (GlobeNewswire)
Sep-29-21 04:10PM	GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-09-21 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial (GlobeNewswire)
Jun-30-21 04:10PM	GENFIT: June 30, 2021 Annual Shareholders Meeting results (GlobeNewswire)
Jun-24-21 04:10PM	GENFIT obtains non-dilutive financing of 11 million in the form of a State Guaranteed Loan (GlobeNewswire)

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

GNFT

Genfit ADR

Upgrade your FINVIZ experience